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Abstract
Introduction: Depletion of cholinergic neurons within the nucleus basalis of Meynert (nbM) is thought to
contribute to the development of cognitive impairments in both Alzheimer’s disease (AD) and Lewy body disorders
(LBD). It has been reported that, in late stage AD, a network of fibres that contain the neuropeptide galanin displays
significant hypertrophy and ‘hyperinnervates’ the surviving cholinergic neurons. Galanin is considered as a highly
inducible neuroprotective factor and in AD this is assumed to be part of a protective tissue response. The aim of
this study was to determine if a similar galanin upregulation is present in the nbM in post-mortem tissue from
patients with LBD. Gallatin immunohistochemistry was carried out on anterior nbM sections from 76 LBD cases
(27 PD, 15 PD with mild cognitive impairment (MCI), 34 PD with dementia (PDD) and 4 aged-matched controls.
Galaninergic innervation of cholinergic neurons was assessed on a semi-quantitative scale.
Results: The LBD group had significantly higher galaninergic innervation scores (p = 0.016) compared to controls.
However, this difference was due to increased innervation density only in a subgroup of LBD cases and this
correlated positively with choline acetyltransferase–immunopositive neuron density.
Conclusion: Galanin upregulation within the basal forebrain cholinergic system in LBD, similar to that seen in
AD, may represent an intrinsic adaptive response to neurodegeneration that is consistent with its proposed
roles in neurogenesis and neuroprotection.
Introduction
Cognitive dysfunction has been increasingly recognised
as an integral feature of Lewy body disorders (LBD). The
severity of cognitive dysfunction and its temporal pres-
entation in relation to Parkinsonian motor symptoms
allows the clinical separation of LBD into Parkinson’s
disease (PD), Parkinson’s disease with dementia (PDD)
and dementia with Lewy bodies (DLB). Although early
cognitive deficits in PD may be caused by failure in mul-
tiple neurotransmitter systems, cholinergic dysfunction
seems to play a significant role in the progression to
dementia [1]. The severe depletion of the basal forebrain
cholinergic neurons in the nucleus basalis of Meynert
(nbM) has long been regarded as a key neuropatho-
logical substrate for cognitive impairment in Alzheimer’s
disease (AD) and LBD [2].
The early vulnerability of the cholinergic system and
other neurotransmitter systems arising from several sub-
cortical nuclei of reticular neurons -the isodendritic core
complex- in LBDs and other dementias [3–6] remains
largely unexplained. However, it was recognised very early
that degeneration of these systems is associated with sig-
nificant plasticity of the surviving neurons [3]. In 1988,
Chan-Palay provided preliminary evidence that in sev-
eral AD cases there was significant hypertrophy of a
network of fibres that innervate the basal cholinergic
neurons (termed hyperinnervation) and contain the
neuropeptide galanin. This was particularly evident in
the anterior nbM [7, 8].
Galanin is a pleiotropic neuropeptide that is widely
distributed within the human nervous system [9, 10] and
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exists as either 19 or 30-amino acid long isoforms
(in contrast to 29 amino acid long as first extracted
from porcine intestines) [11–13]. Galanin is known to
participate in the regulation of several neuroendocrine
[14] and neurotransmitter systems [15, 16] via three gala-
nin G-protein coupled receptors (GAL1-3) [17]. Current
literature suggests that galanin is an important modulator
of the basal cholinergic system [18] and so changes in its
expression may be relevant to the development of demen-
tia. The underlying aetiology and consequences of galani-
nergic hyperinnervation of the nbM neurons are not well
understood but it is currently thought that galanin upreg-
ulation in degenerative tissue may represent a neuropro-
tective mechanism [19] that could be potentially exploited
pharmacologically.
Apart from the descriptive report on galanin hyperin-
nervation of three PDD cases by Chan-Palay [7], there
has not been any investigation of the expression of gala-
nin using contemporary definitions of PD and PDD,
without concurrent AD.
Here, we hypothesise that the extent of galaninergic
innervation within the nbM will increase through the
progression from controls to PD to PDD. The specific
aims of this study were to characterise galaninergic
innervation and expression pattern within the basal fore-
brain region, and to investigate whether the patterns of
innervation differ between PD and PDD.
Materials and methods
Case selection
A total of 177 cases were identified and reviewed from the
Parkinson’s UK Brain Bank at Imperial College London.
Seventy-six LBD cases along with 4 age-matched controls
were selected based on tissue availability. Retrospective
case-note analysis using clinical summaries compiled from
hospital and GP records by movement disorder specialists
and neurologists was undertaken to classify LBD cases
into PD without cognitive impairment, PD with mild cog-
nitive impairment (PD-MCI) and PDD. PD was defined
neuropathologically according to consensus neuropatho-
logical criteria [20] and clinically by presence of 2 out of 4
cardinal motor symptoms (resting tremor, rigidity, hypoki-
nesia and postural instability) [21]. Based on clinical sum-
maries and neuropsychological assessments (if available),
patients with PD who develop cognitive deficits severe
enough to interfere with independent activities of daily
living, satisfying DSM-IV and ICD-10 clinical criteria for
dementia and Movement Disorder Society Task Force
diagnostic criteria for PDD [22], were classified as PDD
on the condition that this developed more than one year
after Parkinsonism symptoms. PD-MCI was defined as a
decline in one or more domains of cognitive function
without significant impairment in the activity of daily
living of the patient [22]. For our exclusion criteria, cases
with poor or incomplete clinical notes and subjects with
last clinician visit more than 2 years prior death were not
included in the present study. Any cases with co-existing
AD pathology (Braak & Braak tau stage 4 or above), cere-
bral vascular pathologies and other co-existing neuro-
pathological diagnosis were excluded. Poorly fixed and
long post-mortem delay of tissue (>72 h) which may
impact on the quality of subsequent immunostaining were
also excluded. In total, 27 cases of PD without cognitive
impairment, 15 cases of PD-MCI and 34 cases of PDD
were selected for this study. Retrospective case-note ana-
lysis is a well-accepted method of case ascertainment and
has often been used in clinic-pathological studies on Lewy
body disorders [23–25].
Definition of the anterior nbM subregion
Following standard protocol, formalin-fixed paraffin-
embedded (FFPE) basal forebrain specimens including
the nbM were cut in the coronal plane in 7 μm thick
sections. The identification of the anterior nbM sub-
region was based on our previously defined boundaries
[2] situated at the level of the decussation of the anterior
commissure and dorsal-lateral to the supraoptic nucleus
(Fig. 1). Magnocellular neurons medial to the supraoptic
neurons were considered part of the Ch2 diagonal band
nucleus.
The selection of the anterior nbM region for this study
is justified given that a) the degeneration of nbM neurons
in this area has been well characterised in both AD and
LBD and b) galanin fibres are more pronounced in the
anterior basal forebrain and anterior nbM compared to
more posterior regions in both health and disease [9, 26].
Galanin immunohistochemistry
FFPE Sections were first dewaxed and rehydrated by se-
quential immersion for 2 × 5 min in xylene and decreas-
ing concentrations of industrial methylated spirit (IMS;
100, 100, 90, 70 %) and distilled water (dH2O). Endogen-
ous peroxidase activity was blocked in 1 % H2O2 in
phosphate-buffered saline (PBS, pH 7.4) for 30 min.
Antigen retrieval was achieved using a steamer (20 min)
in 0.01 M trisodium citrate buffer (pH 6.0). Sections
were then immersed in dΗ2Ο and in PBS (3 × 5 min)
before incubation with a monoclonal galanin antibody
raised against the Ala20-Ser123 peptide portion of hu-
man galanin (1:7000, R&D Systems, MAB585) overnight
at 4 °C (See Additional file 1 for peptide sequence).
On the second day, sections were first immersed in
PBS (2 × 5 min). Sections were visualised with the Super-
Sensitive Link-Label Immunohistochemistry Detection
System (BioGenex, UK) with 3′3-diaminobenzidine
(DAB) according to manufacturer’s manual. All sections
were counterstained with Mayer’s haematoxylin and
dehydrated in increasing concentration of IMS (70, 90,
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100, 100 %) and xylene (2×) before coverslipping with
DPX (Distrene, Plasticiser, Xylene).
Positive controls for the validation of galanin anti-
bodies were sections including hypothalamic nuclei
[9, 10, 27]. The omission of primary antibodies was used
as negative control. The specificity of the galanin antibody
was further investigated with pepsin pretreatment which
digests peptides but not lipofuscin [28]. All negative
controls showed no specific galanin immunoreactivity
(GAL-ir). Staining patterns were also compared with im-
munostaining with a commercial polyclonal antibody
raised against the His51-Lys63 sequence of the human
galanin (See Additional file 1).
However, the potential for cross-reactivity with other
similar antigens cannot be excluded and hence GAL-ir is
regarded as GAL-like immunoreactivity.
Double immunofluorescence of galanin and GFAP
FFPE Sections were dewaxed, rehydrated and pre-
treated as described above. Sections were then incubated
with mouse monoclonal anti-galanin antibody (1:1000,
R&D Systems, MAB585) and rabbit polyclonal anti-glial
fibrillary acidic protein (GFAP, 1:500, Dako, Z0334)
diluted in PBS with 2 % goat serum and 0.3 % Triton-X
100 overnight at 4 °C. On the second day, sections were
first immersed in PBS (2 × 5 min), then incubated with
goat-anti-mouse secondary antibody conjugated with
Alexa Fluor® 568 fluorophore (1:200, ThermoFisher
Scientific, A-11004) and goat-anti-rabbit secondary
antibody conjugated with Alexa Fluor® 488 fluorophore
(1:200, ThermoFisher Scientific, A-11008) for 1 h at
room temperature. Sections were then rinsed briefly in
PBS (3 × 5 min) and incubated in 1 % sudan black B
dissolved in 70 % ethanol to block endogenous autofluo-
rescence by lipofuscin, before coverslipping and mounting
with VECTASHEILD antifade mounting medium with
DAPI (Vector Laboratories, UK).
Semi-quantitative scoring of galaninergic innervation
As reported in the literature, the absolute quantification
of GAL-ir terminals and innervation is technically diffi-
cult [7, 26, 29, 30]. Hence a semi-quantitative scale with
four grades was devised (Fig. 2). All sections were
stained with a monoclonal antibody against galanin. A
photomicrograph of the area of maximal innervation
within the limits of the anterior nbM from each stained
section were captured on an Olympus AHBT3 VANOX
microscope with digital camera at ×200 magnification.
The images were individually graded according to the
semi-quantitative scale by two independent assessors
(AA, AKLL) blinded to diagnosis. For inter-rater reli-
ability, Cohen’s κ = 0.86 and weighted κ = 0.92 (SE of
κ = 0.13). For intra-rater reliability, Cronbach’s α =
0.98. These reliability coefficient scores indicate an
excellent inter- and intra-rater reproducibility of the
semi-quantitative grading.
Fig. 1 Drawing of a H&E-stained section through the anterior nucleus basalis of Meynert. AC anterior commissure, BNST bed nucleus of stria
terminalis, Ca caudate nucleus, GPe/i globus pallidus externus/internus, IC internal capsule, LV lateral ventricle, nbM nucleus basalis of Meynert
(grey area represents expected distribution), Put putamen, SND sexually dimorphic nucleus of the preoptic area, S septum, SON supraoptic nucleus
Alexandris et al. Acta Neuropathologica Communications  (2015) 3:77 Page 3 of 12
Confocal microscopy
Imaging of double immunofluorescence-stained tissues
was performed using a Zeiss LSM-780 inverted con-
focal laser scanning microscopes (Carl Zeiss, Germany)
at the Facility for Imaging by Light Microscopy (FILM)
facility in Hammersmith Hospital. A ×10 objective (EC
Plan-Neofluar, numerical aperture, 0.3; working distance,
5.2 mm) and ×20 objective (Plan Apochromat DIC, nu-
merical aperture, 0.8; working distance, 0.55 mm) with
laser excitation at 405, 488, 543 and 594 nm were used.
Image capturing and processing were performed using the
Zen Black (Carl Zeiss, Germany) software.
Statistical analysis
Demographic characteristics were tested for normality
with the Shapiro-Wilk test and visual inspection of
Q-Q plots, and then compared with one-way ANOVA
(F). The Mann-Witney test (U) was used to test the
one-tailed hypothesis that disease cases will have
increased innervation compared to controls. The
Kruskal-Wallis test (H) with post-hoc pairwise com-
parison was used for analysis of innervation scores
among different diagnostic groups. Spearman rank
correlation (rho) was used for non-parametric analysis
of associations. Statistical significance was set at p <
0.05. Non-adjusted p-values are shown. Statistical ana-
lyses were performed on IBM Statistical Package for
Social Sciences software (SPSS v22) and GraphPad
Prism 6 software.
Results
Cohort characteristics
For the 3 cohorts included in this study (Table 1) the
age at disease onset, age at death and sample region, did
not differ significantly between groups, although most of
them were male due to tissue availability limitations.
Argyrophilic grain pathology is very common and was
found in one PDD and one PD-MCI case but it is not
thought to represent a separate pathological/nosological
entity [31]. Control cases had no significant α-synuclein
or tau pathology.
General patterns of galanin-like immunoreactivity
In accordance with observations made previously [8–10,
26, 27] intensely stained bipolar and multipolar neurons
were observed in the medial and lateral hypothalamus
(Fig. 3a) in both control and disease cases. A few
intensely GAL-ir parvicellular neurons and dense fibres
were also observed in the neighbouring sexually di-
morphic nucleus of the preoptic area (intermediate nu-
cleus; Fig. 3b), already known to be galaninergic [32].
Galanin-immunoreactive fibres were intensely stained
and widely distributed in all sections. A high density of
galaninergic fibres dorsomedial to nbM was always
present and in line with a proposed galaninergic path-
way that courses through the substantia innominata
(sub-commissural region) en route to the hypothalamus,
bed nucleus of the stria terminalis and the nucleus of the
vertical limb of diagonal band (Ch2) [8, 9].
Fig. 2 Galanin innervation semi-quantitative scale. a Grade 0, no visible innervation. b Grade 1, minimal innervation. Fibres in the neuropil are
sparse. c Grade 2, moderate innervation. Many thick fibres in the neuropil and several contacts with somata/dendrites. d Grade 3, Hyperinnervation.
Abundant hypertrophic fibres in the neuropil with frequent contacts with neurons
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Table 1 Summary of clinical characteristics. See text for discussion
Mean age
at onset (SD)
Mean age
at death (SD)
Mean duration
of disease (SD)
Median Braak α-synuclein stage Median Braak tau stage % of Males
CONTROLS (n = 4) – 82.75 (5.11) – 0 2 25.0
PD (n = 27) 66.59 (8.58) 77.48 (7.15) 10.93 (6.01) 6 2 55.6
PD-MCI (n = 15) 60.93 (9.95) 75.20 (8.45) 14.40 (6.31) 6 1 53.3
PDD (n = 34) 63.88 (10.31) 77.12 (8.13) 13.35 (5.58) 6 2 70.6
Fig. 3 Different patterns of galanin immunoreactivity in the basal forebrain. a Intensely immunoreactive neurons of the hypothalamic nuclei.
b Galanin immunoreactive neurons and fibres in the sexually dimorphic nucleus of the preoptic area, also known as intermediate hypothalamic
nucleus (20×). c-d Spectrum of perikaryal immunoreactivity within the neurons of the supraoptic nucleus. e-h putative glia with GAL-ir of radial
morphology found within the ventral pallidum (E captured at 20×; F-H captured at 40×; scale-bar for F-H)
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Intense somal GAL-ir was observed in the hypothalamic
nuclei (Fig. 3a-b) and the supraoptic nucleus (SON) exhib-
ited variable levels of perikaryal staining and very few
fibres (Fig. 3c-d). Some somal GAL-ir was observed in the
nbM and sections from the same case immunostained with
galanin and ChAT antibodies reveal immunoreactivity of
the same magnocellular cell population (Fig. 4a-b). It was
noticed that there was no concordance between perikaryal
staining intensity in the SON and that of the neighbouring
nbM neurons. Confocal microscopy demonstrated low
level galanin immunofluorescence in both SON and nbM
magnocellular neurons (Fig. 5a-b).
Finally, GAL-ir of a radial morphology (25–50 μm in
diameter) consistently with a putative glial cell nucleus
at the epicentre (10–15 μm), was observed predomin-
ately dorso-laterally to the nbM, within the ventral palli-
dum (Fig. 2e-h). These putative glial cells with GAL-ir
were observed in about half of the disease cases and in
none of the controls, being more frequent and more
prominent in PDD and less so in PD-MCI and PD cases.
GFAP immunostaining of adjacent slides and confocal
microscopy revealed no co-localization of galanin with
the astrocytic marker (Fig. 5c).
Galaninergic innervation of putative cholinergic neurons
GAL-ir fibres were nearly always visualised within the
nbM although their density was very variable. GAL-ir
fibres were found to course through the neuropil and to
decorate the somata and the dendritic tree of putative
cholinergic neurons to different extents (Fig. 2). The
very close apposition between the fibres’ varicosities and
the magnocellular cell bodies and proximal dendrites
suggests the existence of synaptic contacts (Fig. 4d-e).
However, as the distal dendritic tree of the magnocellu-
lar neurons was not visible we cannot exclude further
contacts with the ‘free’ galanin fibres. Direct apposition
between fibres and neurons has been demonstrated pre-
viously with confocal microscopy [29] while synaptic
Fig. 4 Galanin like immunoreactivity (GAL-ir) of putative cholinergic neurons. a-b Sections of ChAT (a) and galanin (b) immunostaining of the
nucleus basalis magnocellular neurons from the same case; * denotes same anatomical landmark. c Example of minimal somal immunoreactity.
d Example of intense perikaryal GAL-ir. e-f Galaninergic innervation of putative cholinergic neurons (arrow heads)
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contacts between galanin-positive fibres and choline
acetyltransferase (ChAT)-positive neurons have been
characterised in the rat using electron microscopy
[33]. In a subgroup of disease-cases there was pro-
found hypertrophy of the galaninergic fibre network
in terms of increased fibre density and varicosities
and increased perikaryal decoration, similar to the
hyper-innervation pattern described previously in AD
[7, 8, 29, 30].
Semi-quantitative assessment of innervation density
revealed that the extent of innervation was significantly
higher in LBD (PD, PD-MCI and PDD combined)
compared to the age-matched controls; U(78) = 57.00,
Z = −2.219, exact p = 0.016 (one-tailed; see Fig. 6a).
Further, analysis indicated no significant differences
among the different diagnostic groups although it was
noticed that the PD-MCI group had more cases dis-
playing hyperinnervation compared to PD and PDD
groups (Fig. 6b).
Secondary analysis: galaninergic innervation, cholinergic
cell density, Braak staging and demographics
We have also explored further associations regarding gala-
ninergic innervation within our cohort (non-adjusted,
two-tailed p-values are presented) that may give hints into
the role and mechanisms of galaninergic innervation.
Analysis of the LBD cohort revealed a small but
significant correlation between innervation grade and
maximum density cell count; Spearman’s rho = 0.361,
p = 0.005. See Fig. 7. Maximum cell density count of
ChAT +ve neurons from adjacent sections was obtained
from on-going projects [34] in our lab (n = 60). This trend
was preserved after subgroup analysis but did not reach
statistical significance probably due to low power (PD:
rho = 0.398, p = 0.066; PD-MCI: rho = 0.674, p = 0.067;
PDD: rho = 0.127, p = 0.520). Direct comparison of in-
nervation grade 0 (n = 8) and grade 3 (n = 16) cases
showed that in the hyper-innervated cases the mean
maximum cell density was nearly twice that of the non-
Fig. 5 GFAP and galanin immunofluorescence with confocal microscopy. a Supraoptic nucleus showing galanin immunofluorescence of perikarya
(×10) b Nucleus basalis of Meynert showing putative cholinergic neurons with perikaryal galanin immunofluorescence. c Ventral pallidum
showing lack of association between glial galanin-like immunoreactivity and the astrocytic marker GFAP (×20)
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hyper-innervated ones. See Table 2. We also found a
negative correlation between galaninergic innervation
and Braak tau staging, Spearmans’ rho = −0.245, p =
0.035; but not with Braak α-synuclein.
Finally, although the control group was predomin-
antly female, group and subgroup analysis revealed no
significant differences between males and females
regarding galaninergic innervation. We also found no
significant correlations between galaninergic innervation,
age at onset, age at death or duration of disease.
Discussion
Galaninergic innervation and hyper-innervation
This is the first study to our knowledge that has charac-
terised and semi-quantitatively analysed the immunore-
activity of galanin in the nbM of brains of patients with
LBD. The finding of significantly increased innervation
density in LBD compared to age-matched controls is in
line with previous literature on AD [7, 8, 29]. Yet, here
we report that increased innervation or hyper-innervation
(grades 2 and 3 innervation) was observed in only half of
Fig. 6 a Semiquantitative assessment of galaninergic innervation of nucleus basalis of Meynert in Parkinson’s disease (PD) without or with mild
cognitive impairment (PD-MCI), Parkinson’s disease dementia (PDD), and age-matched controls. Horizontal bars indicate the median value with
interquartile range. b Percentage of cases displaying different innervation scores within each diagnostic category. For explanation of grading
system see text
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all LBD cases. Interestingly, the PD-MCI group had the
highest proportion of cases displaying grade 3 hyperinner-
vation although we found no statistically significant differ-
ences among the different LBD groups, probably because
of the relatively low number of cases. Whether this trend
indicates a real activation of the galanin system during the
transition from PD to PDD is difficult to know but would
be of interest, as Lewy body pathology in the nbM and
loss of cholinergic neurons occurs early in PD. In that
sense, an inverted U-shape curve would be consistent with
an early compensatory reactivity of the galanin system
against cognitive dysfunction that may fail in later stages
of the disease. In contrast, one similar study [30] assessed
galaninergic innervation of anterior nbM neurons in
samples of patients with early AD, mild cognitive impair-
ment, and no cognitive impairment, but revealed no dif-
ferences among groups with regards to innervation scores
or correlation with cell counts. The authors suggested that
hyper-innervation may occur in late rather than early
stage AD but a direct comparison between AD and LBD
has not been undertaken to our knowledge. Interestingly,
in secondary analysis we observed a negative but weak
correlation between innervation grade and Braak tau
staging. Although this could be a type 1 error (false posi-
tive), further examination and quantification of tau, β-
amyloid and α-synuclein pathology may elucidate further
any potential associations with galanin.
The exact aetiology of galanin fibre plasticity is still
largely unresolved but it is thought to relate to local or
distant injury of the cholinergic basocortical pathways.
Yet, although hyper-innervation may indeed be more
common in AD or LBD, the fact that increased innerv-
ation occurs only in a subgroup of disease cases implies
that it is a secondary reactive phenomenon and not inte-
gral to the underlying degenerative processes. Increased
GAL-ir fibre density has been observed in the rat basal
forebrain after direct excitotoxic lesions of basal cholin-
ergic groups [35, 36] and even ischaemic lesions of
cortical target sites [37]. Immunotoxic lesioning of the
cholinergic neurons of the horizontal limb of the diag-
onal band of Broca (Ch3) in the rat with the cholinergic
specific 192 IgG-saporin also produces increases in
GAL-ir fibre density and thickness that occur as early as
one hour and persist for up to 6 months [38]. In these
animal studies an increase in fibre density is observed
after a single insult, irrespective of the resultant cholin-
ergic cell loss [38]. However, in AD [30] or LBDs, which
are progressive, hyper-innervation is not observed in the
prodromal or early stages of the disease. Hence, it is still
not clear whether hyper-innervation occurs as a direct
response to neuronal injury or as part of a feedback
mechanism related to the functional status of the cholin-
ergic neurons. Imbalances in excitatory/inhibitory input
or output are already known to upregulate galanin in a
different paradigm [39].
Furthermore, old rats (20 months old) not only fail to
elicit a galanin response to an excitotoxic insult in the
nbM compared to young rats, but also show a lower
baseline GAL-ir fibre density [35]. Similarly, partial fail-
ure of somal galanin upregulation has been observed in
the Ch1-Ch2 neurons of old rats after colchicine treat-
ment, which is known to impair fast axonal transport
[40]. The underlying reasons for the decreased galanin
Fig. 7 Correlation between innervation scores and maximum
density counts of ChAT +ve neurons from adjacent sections (n = 60)
in Lewy body disease cases. Mean value for every grade is shown
with a horizontal bar. Spearman’s rho = 0.361, p = 0.005
Table 2 Characteristics of Lewy body disease cases grouped by innervation grade
Innervation Score Mean age
at onset (SE)
Mean age
at death (SE)
Mean duration
of disease (SE)
Mean ChAT +ve
neuron count (SE)*
Median Braak α-synuclein stage Median Braak tau stage **
0 (n = 8) 70.12 (2.546) 78.75 (2.987) 8.63 (1.451) 68.88 (19.59) 6 2
1 (n = 33) 63.55 (1.757) 76.61 (1.302) 13.15 (1.085) 89.33 (11.716) 6 2
2 (n = 19) 63.42 (1.955) 77.47 (1.885) 14.11 (1.395) 111.62 (20.3) 6 2
3 (n = 16) 63.81 (2.802) 75.75 (2.044) 12.13 (1.378) 120.38 (13.581) 6 2
*Spearmans’ rho = rho = 0.361, p = 0.005. ** rho = −0.245, p = 0.035
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plasticity in the old rats are not known but would be of
great relevance to neurodegenerative conditions and
might explain why hyper-innervation is observed only in
a subgroup of cases. In our study, however, we found no
significant correlation between demographics and extent
of innervation.
After secondary analysis within the LBD cohort, we
also found a significant correlation between innervation
score and ChAT +ve neuronal count and interestingly
the 8 cases with very scant galanin fibres (grade 0) not
only had a very low cell count, but also a faster disease
course and were older age at death compared to the
hyper-innervated cases (Table 2). There is already some
evidence that galaninergic hyper-innervation in AD is
associated with favourable expression of pro-survival
mRNAs, as determined by single cell gene expression
profiling, and it has also been argued that the caudo-
rostral pattern of degeneration of the nbM neurons in
AD is related to the reduced galaninergic innervation of
the more posterior aspects of the nbM [19, 41]. It would
be tempting to consider then that the observed positive
correlation is supportive of the neuroprotective role of
galanin as suggested previously [19]. However, the de-
sign of this study cannot reveal whether such a correl-
ation is causal or whether this just indicates that lower
cell density means less available neurons for innervation
(n.b. this would not hold true for the healthy controls).
nbM Somal GAL-ir and neuronal injury
Previous literature has been contradictory with regards
the presence or not of galanin within the somata of the
cholinergic neurons of the nbM. Although there have
been previous immunohistochemical observations of
moderate GAL-ir within the nbM cholinergic neurons of
elderly control and AD brains [7, 10, 42, 43] it has also
been supported that galanin is expressed by basal cholin-
ergic neurons only in non-human primates and not in
the normal or diseased human brain [8, 9, 26, 30, 41,
44]. Similarly, in an RNA hybridization study by Walker
et al. [44] there was no co-localization of the galanin
RNA probe (directed against bases 228–271 of the rat
galanin sequence) and cholinergic neurons in the hu-
man nbM, which could be because of the use of a
reportedly high threshold. In contrast, in another
hybridization study by Chan-Palay et al. [59], using a
different probe (directed against bases 324–414 of por-
cine galanin), mRNA labeling did co-localize with
medium-sized nbM neurons and was also slightly in-
creased in AD [45].
In the present study variable perikaryal galanin-like
immunoreactivity within magnocellular neurons in the
nbM was observed in a number of disease cases. How-
ever, although the antibody used is monoclonal and by
definition selected and purified for its affinity towards a
recombinant human galanin peptide, it is not possible to
exclude cross-reactivity with other epitopes and regard-
ing this as intrinsic upregulation of galanin would be still
speculative at this point.
Nevertheless, a potential upregulation of galanin within
the human cholinergic neurons would be consistent
with several animal models of neuronal injury: Signifi-
cant increases in the number of GAL-ir neurons, gala-
nin peptide levels (up to 120-fold) and galanin-mRNA
levels have been observed after transection of the rat
sciatic nerve [46, 47] or lesions of rat basal cholinergic
neurons, their projections and their targets [38, 48, 49].
Upregulation of galanin peptide and mRNA can also be
induced by colchicine [43] or tetrodotoxine [49]. All
these indicate that physical or functional disruption of
axonal homeostasis is sufficient for the reactive upregu-
lation of galanin within the affected cholinergic
neurons. Therefore, the observed increases in somal
GAL-ir in a subgroup of disease cases might relate to
the underlying neuronal injury and may represent en-
dogenous synthesis due to auto-regulation [50]. Follow-
ing this up, we have preliminary observations that some
cases with moderate somal GAL-ir, display somal APP
immunoreactivity as well, which is a marker of axonal
dysfunction (Fig. 8). The presence or not of galanin
within the human cholinergic neurons and its potential
relationship with axonal dysfunction will be addressed
in future studies.
Fig. 8 APP immunostaining of nucleus basalis neurons indicating axonal dysfunction in a case associated with perikaryal galanin-like immunoreac-
tivity (GAL; scale bar represents 100 μm)
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Other types of GAL-ir
Finally, the very isolated observation of the putative glia
associated with radial GAL-ir (§3.3) in the ventral palli-
dum is a finding of yet unknown significance and the
identity of the associated cells remains unknown. This
potential and site-specific association and the observed
predominance in PDD cannot be explained and necessi-
tates further validation and investigation.
Conclusion
This is the first study to provide evidence of increased
galanin innervation and possibly somal expression
within nbM neurons, in Lewy body disorders without
concurrent significant AD pathology. The reason that
this response is observed only in a subgroup of disease
cases remains rather elusive and this heterogeneity
emphasises that galanin upergulation is not an integral
part of neurodegeneration but probably a secondary
reactive phenomenon. Future research would benefit
from inclusion of corroborating techniques that can con-
fidently assess the presence and quantify the levels of
galanin mRNA and peptide. Clinicopathological correla-
tions in well-characterised cohorts would then be of im-
portance as well as the direct comparison between LBD
and AD. Finally, the development of quantitative
approaches is necessary for giving a confident answer to
the question of whether basal forebrain galanin upregu-
lation occurs in different neurodegenerative conditions
including AD.
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